Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-center, Open-Label, Dose Escalation Study Evaluating the Safety of in Vivo Administration of FEIBA in Congenital Hemophilia A Patients With Inhibitors on Emicizumab

NCT04205175 is registered in ClinicalTrials.gov with Children's Hospital Los Angeles as lead sponsor.

NCT NCT04205175
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04205175 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-center, Open-Label, Dose Escalation Study Evaluating the Safety of in Vivo Administration of FEIBA in Congenital Hemophilia A Patients With Inhibitors on Emicizumab
Lead sponsor
Children's Hospital Los Angeles
Phase
Phase 4
Overall status
Active, not recruiting
Start date
July 1, 2020
Completion date
October 31, 2022
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hemophilia a with inhibitor